# CELEB: Lung volume reduction in COPD - surgery

Submission date	Recruitment status No longer recruiting	[X] Prospectively registered		
23/05/2016		[X] Protocol		
Registration date	Overall study status Completed	Statistical analysis plan		
23/05/2016		[X] Results		
<b>Last Edited</b> 03/05/2023	Condition category Respiratory	[] Individual participant data		

## Plain English summary of protocol

Background and study aims

Chronic obstructive pulmonary disease (COPD) is the collective name for a group of diseases which affect the lungs. One of the diseases is emphysema, a lung condition in which the tiny air sacs (alveoli) in the lungs become damaged over time. In emphysema, the alveoli become overfilled with air, causing the walls to weaken and eventually burst, creating one larger air space instead of many small ones. This means that the sufferer is unable to breathe out fully, leading to breathlessness which becomes progressively worse. Lung volume reduction surgery (LVRS) is an operation in which the worst affected part of the lung is removed, making more space for the remaining healthier lung to function. There is good evidence that in properly selected individuals this can improve breathlessness and increase life expectancy. It is a major operation and does carry a risk of complications however. A more recent approach is to use a fibreoptic camera (bronchoscope) to place valves into the airways of the lung. These stop air from entering the worst-affected section of the lung causing it to collapse, leading to similar benefits of LVRS. The aim of this study is to compare the effectiveness of these two techniques in the treatment of patients with emphysema.

## Who can participate?

Adults with a heterogeneous pattern of emphysema (isolated to certain areas of the lungs and to a varying extent between segments of the lungs)

#### What does the study involve?

Participants are randomly allocated to one of two groups. Those in the first group undergo lung volume reduction surgery. Those in the second group have endobronchial valves placed into their airways using a bronchoscope while they are sedated. One year after the procedures, participants in both groups undergo a number of physical tests to find out if their lung function has improved as well as their overall quality of life.

What are the possible benefits and risks of participating? Not provided at time of registration

Where is the study run from?

- 1. Royal Brompton Hospital (UK)
- 2. Glenfield Hospital (UK)
- 3. St Bartholomew's Hospital (UK)

- 4. Northern General Hospital (UK)
- 5. Golden Jubilee National Hospital (UK)

When is the study starting and how long is it expected to run for? April 2016 to September 2020

Who is funding the study? National Institute for Health Research (UK)

Who is the main contact? Sara Buttery s.buttery@rbht.nhs.uk

## **Contact information**

## Type(s)

Scientific

#### Contact name

Ms Sara Buttery

#### Contact details

Royal Brompton Hospital Fulham Road London United Kingdom SW3 6NP +44 (0)207 351 8029 s.buttery@rbht.nhs.uk

## Additional identifiers

Protocol serial number

30523

## Study information

#### Scientific Title

The CELEB trial: Comparative Effectiveness of Lung volume reduction surgery for Emphysema and

### Acronym

**CELEB** 

## Study objectives

The aim of this study is to evaluate the relative effectiveness and value of two options currently available for the treatment of COPD patients with a heterogeneous pattern of emphysema. These are lung volume reduction surgery (LVRS) and the bronchoscopic placement of endobronchial valves (BLVR).

## Ethics approval required

## Old ethics approval format

## Ethics approval(s)

London - Fulham Research Ethics Committee, 18/02/2016, ref: 16/LO/0286

## Study design

Interventional; Design type: Treatment, Device, Surgery

## Primary study design

Interventional

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Emphysema

#### **Interventions**

Patients will be randomised to either unilateral video assisted thoracoscopic (VATS) lung volume reduction surgery (LVRS) or endobronchial valves (BLVR) placed to achieve lobar occlusion.

#### Intervention Type

Device

## Primary outcome(s)

Change in iBODE score (a composite of BMI, FEV1, MRC dyspnoea score and shuttle walk test distance) one year post procedure.

## Key secondary outcome(s))

- 1. Health related quality of life is measured using the COPD assessment test score (CAT)
- 2. Physical activity level
- 3. Change in residual volume (RV)
- 4. Fat free mass

## Completion date

30/09/2020

## **Eligibility**

#### Key inclusion criteria

- 1. Adults (aged 18 or over) with COPD
- 2. FEV1 <60% predicted
- 3. Significant hyperinflation (TLC>100% predicted, RV>170% predicted)
- 4. Ex-smoker >3 months
- 5. MRC dyspnoea score 3 or more

6.

CT scan assessed at MDT to have intact interlobar fissures (>90%) and heterogeneous emphysema

7. Provision of informed consent to participate

## Participant type(s)

**Patient** 

## Healthy volunteers allowed

No

## Age group

Adult

## Lower age limit

18 years

#### Sex

All

### Total final enrolment

88

### Key exclusion criteria

- 1. Smoking within 3 months
- 2. CT scan shows interlobar fissures are not intact
- 3. Major comorbidity limiting survival
- 4. Significant pulmonary fibrosis
- 5. FEV1 and TLco < 20%
- 6. PaO2 < 7.0kPa
- 7. PaO2 > 7kPa
- 8. Presence of interlobar collateral ventilation assessed by Chartis system

#### Date of first enrolment

01/06/2016

### Date of final enrolment

01/06/2019

## Locations

#### Countries of recruitment

**United Kingdom** 

England

Scotland

## Study participating centre Royal Brompton Hospital

Fulham Road London United Kingdom SW3 6NP

## Study participating centre Glenfield Hospital

University Hospitals Leicester United Kingdom LE3 9QP

Study participating centre
St Bartholomew's Hospital
Barts Health NHS Foundation Trust
United Kingdom
EC1A 7BE

Study participating centre Northern General Hospital Sheffield United Kingdom S5 7AU

Study participating centre Golden Jubilee National Hospital Glasgow United Kingdom G81 4DY

## Sponsor information

## Organisation

Royal Brompton and Harefield NHS Foundation Trust

#### **ROR**

https://ror.org/02218z997

## Funder(s)

## Funder type

Government

#### Funder Name

National Institute for Health Research

### Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

## **Funding Body Type**

Government organisation

## **Funding Body Subtype**

National government

#### Location

**United Kingdom** 

## **Results and Publications**

## Individual participant data (IPD) sharing plan

Not provided at time of registration

## IPD sharing plan summary

Data sharing statement to be made available at a later date

## **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		27/04/2023	03/05/2023	Yes	No
Protocol article	protocol	17/10/2018	30/10/2019	Yes	No
HRA research summary			28/06/2023		No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes